Bauer Mark S, Wisniewski Stephen R, Marangell Lauren B, Chessick Cheryl A, Allen Michael H, Dennehy Ellen B, Miklowitz David J, Thase Michael E, Sachs Gary S
Providence Veterans Affairs Medical Center and the Department of Psychiatry and Human Behavior, Brown University, VAMC-116R, 830 Chalkstone Avenue, Providence, R.I. 02908-4799, USA.
J Clin Psychiatry. 2006 Jan;67(1):48-55. doi: 10.4088/jcp.v67n0108.
Depressive episodes are common in bipolar disorder, and the disorder is characterized by high suicide rates. Recent analyses indicate a possible association of antidepressant treatment and suicidality in children and adults with depressive or anxiety disorders. However, few data are available to inform the suicidality risk assessment of antidepressant use specifically in bipolar disorder.
Of the first 2000 participants followed for 18 months in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), 425 experienced a prospectively observed, new-onset major depressive episode without initial suicidal ideation. Standardized ratings of suicidality and antidepressant exposure at index depressive episode and next evaluation were used to investigate the primary hypothesis that new-onset suicidality was associated with increased antidepressant exposure (antidepressant initiation or dose increase). Secondary analysis investigated correlates of new-onset suicidality and antidepressant exposure. Data were collected from November 8, 1999, to April 24, 2002.
Twenty-four participants (5.6%) developed new-onset suicidality at follow-up, including 2 suicide attempts. There was no association of new-onset suicidality with increased antidepressant exposure or any change in antidepressant exposure, and no association with initiation of antidepressant treatment. New-onset suicidality was associated with neuroticism, prior attempt, and higher depressive or manic symptom ratings at index episode. Increased antidepressant exposure was negatively associated with higher manic symptom rating at index episode; control for this sole empirically identified confound did not alter the primary results.
Although careful monitoring for suicidality is always warranted in bipolar disorder, this cohort study provides no evidence that increased antidepressant exposure is associated with new-onset suicidality in this already high-risk population. Correlates of both suicidality and antidepressant exposure indicate directions for further research.
抑郁发作在双相情感障碍中很常见,且该疾病的特点是自杀率高。近期分析表明,抗抑郁药治疗与患有抑郁或焦虑症的儿童及成人的自杀行为之间可能存在关联。然而,关于抗抑郁药在双相情感障碍中使用的自杀风险评估,可用数据很少。
在双相情感障碍系统治疗强化项目(STEP - BD)中,对最初随访18个月的2000名参与者进行研究,其中425人经历了前瞻性观察到的新发重度抑郁发作且最初无自杀意念。在索引抑郁发作和下次评估时,对自杀行为和抗抑郁药暴露进行标准化评分,以研究主要假设,即新发自杀行为与抗抑郁药暴露增加(开始使用抗抑郁药或增加剂量)有关。二级分析研究了新发自杀行为和抗抑郁药暴露的相关因素。数据收集时间为1999年11月8日至2002年4月24日。
24名参与者(5.6%)在随访时出现新发自杀行为,包括2次自杀未遂。新发自杀行为与抗抑郁药暴露增加或抗抑郁药暴露的任何变化均无关联,与开始抗抑郁药治疗也无关联。新发自杀行为与神经质、既往自杀未遂以及索引发作时更高的抑郁或躁狂症状评分有关。抗抑郁药暴露增加与索引发作时更高的躁狂症状评分呈负相关;对这一唯一经实证确定的混杂因素进行控制并未改变主要结果。
尽管在双相情感障碍中始终有必要仔细监测自杀行为,但这项队列研究没有证据表明,在这个已经处于高风险的人群中,抗抑郁药暴露增加与新发自杀行为有关。自杀行为和抗抑郁药暴露的相关因素为进一步研究指明了方向。